ECSP12011740A - ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME - Google Patents

ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME

Info

Publication number
ECSP12011740A
ECSP12011740A ECSP12011740A ECSP12011740A EC SP12011740 A ECSP12011740 A EC SP12011740A EC SP12011740 A ECSP12011740 A EC SP12011740A EC SP12011740 A ECSP12011740 A EC SP12011740A
Authority
EC
Ecuador
Prior art keywords
erbb3
antibodies
antigen
receptor
binding fragments
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of ECSP12011740A publication Critical patent/ECSP12011740A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de anticuerpos y fragmentos de unión a antígeno de los mismos que se unen al dominio extracelular del receptor ErbB3 e inhiben diversas funciones de ErbB3. Por ejemplo, los anticuerpos y fragmentos de unión a antígeno descritos en la presente son capaces de unirse al receptor designado ErbB3 e inhibir la fosforilación mediada por ligando similar a EGF del receptor. Dichos anticuerpos y fragmentos de unión a antígeno de los mismos tiene la característica útil de inhibir la proliferación de células cancerígenas que expresan ErbB3.The present invention provides a new class of antibodies and antigen-binding fragments thereof that bind to the extracellular domain of the ErbB3 receptor and inhibit various functions of ErbB3. For example, the antibodies and antigen-binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand-mediated phosphorylation of the receptor. Said antibodies and antigen-binding fragments thereof have the useful feature of inhibiting the proliferation of cancer cells expressing ErbB3.

ECSP12011740 2009-08-21 2012-03-21 ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME ECSP12011740A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
ECSP12011740A true ECSP12011740A (en) 2013-02-28

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011740 ECSP12011740A (en) 2009-08-21 2012-03-21 ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (en) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Antibodies to ERBB3 and uses thereof
EP2896632B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
RS54795B1 (en) 2009-12-22 2016-10-31 Roche Glycart Ag ANTI-HER3 ANTIBODIES AND THEIR USES
KR101798679B1 (en) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
MX343227B (en) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc ANTI-ERBB3 ANTIBODIES.
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
MX347981B (en) 2010-11-01 2017-05-22 Symphogen As Pan-her antibody composition.
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
JPWO2012176779A1 (en) 2011-06-20 2015-02-23 協和発酵キリン株式会社 Anti-erbB3 antibody
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
JP6169085B2 (en) 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド Estimation of tumor response to anti-ERBB3 antibody
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP6771385B2 (en) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ Bispecific antibody and pharmaceutical composition
CN105367657B (en) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 Anti-HER3 antibody, its preparation method and application
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SMT202100230T1 (en) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Binding molecules that inhibit cancer growth
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
JP7296891B2 (en) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ Combining ErbB-2/ErbB-3 bispecific antibodies with endocrine therapy for breast cancer
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CA3072267A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan Her3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (en) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド Anti-HER3 antibody and its uses
JP7847132B2 (en) * 2020-10-14 2026-04-16 江蘇恒瑞医薬股▲ふん▼有限公司 Anti-HER3 antibodies, anti-HER3 antibody-drug conjugates, and their pharmaceutical applications
WO2022109404A1 (en) * 2020-11-20 2022-05-27 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (en) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Antibodies to ERBB3 and uses thereof

Also Published As

Publication number Publication date
PE20121585A1 (en) 2012-11-29
AU2010284018B2 (en) 2014-06-05
MX336091B (en) 2016-01-08
ZA201201195B (en) 2015-07-29
WO2011022727A3 (en) 2013-06-27
KR20120059568A (en) 2012-06-08
MX2012002172A (en) 2012-05-29
TN2012000057A1 (en) 2013-09-19
JP2013506622A (en) 2013-02-28
IN2012DN01518A (en) 2015-06-05
EA201200195A1 (en) 2012-12-28
BR112012003809A2 (en) 2019-09-24
WO2011022727A2 (en) 2011-02-24
IL218097A0 (en) 2012-04-30
AU2010284018A1 (en) 2012-03-22
JP5752687B2 (en) 2015-07-22
CA2771744A1 (en) 2011-02-24
NI201200027A (en) 2013-01-29
MA33582B1 (en) 2012-09-01
CN103002912A (en) 2013-03-27
SG178509A1 (en) 2012-04-27
AU2010284018C1 (en) 2015-10-15
DOP2012000044A (en) 2012-06-30
CR20120108A (en) 2012-06-05
EP2467164A2 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
ECSP12011740A (en) ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME
ECSP099637A (en) ANTIBODIES AGAINST ERBB3 AND THE USES OF THE SAME
CY1118761T1 (en) CODES FOR RECEPTORING GROWTH FACTORS 3 (HER3)
CR20140146A (en) ANTI-BODIES ANTI-CD134 (OX40) AND USES OF THE SAME
CY1119154T1 (en) ANTI-VLA-4 ANTIBODIES
CO2020006453A2 (en) Anti-cxcr5 antibodies and compositions and uses thereof
CL2017002641A1 (en) Bispecific antibody constructs against cdh3 and cd3
CR20110566A (en) IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
CR20150493A (en) AMRI COMPOSITIONS AGAINST COMPONENT C5 OF THE COMPLEMENT AND METHODS FOR USE
TR201910959T4 (en) Application of electromagnetic radiation to the human iris.
MX2014009289A (en) ANTIBODIES C1ORF32 AND USES OF THE SAME FOR THE TREATMENT OF CANCER.
MX369740B (en) Antibodies against claudin 18.2 useful in cancer diagnosis.
CR20140585A (en) ST2 ANTIGEN UNION PROTEINS
MX2018003196A (en) ANTI-PROMIOSTATIN OR LATENT MIOSTATINE ANTIBODIES AND USES OF THE SAME.
MX2014015830A (en) Lsr antibodies, and uses thereof for treatment of cancer.
UY35399A (en) CONJUGATES OF DRUGS WITH ANTIBODIES
CR20120577A (en) ANTIBODIES TO GDF8 HUMAN
CR20150634A (en) HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE LIGANDS D1
NZ710929A (en) Antibody drug conjugates
MX2013010475A (en) IMMUNOTHERAPEUTIC COMPOSITIONS OF LEVADURA-BRACHYURI.
CU20140073A7 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES ACTING ON FACTOR P
CO6470896A2 (en) COMPOUNDS THAT SELECTLY MODULATE THE CB2 RECEIVER
BR112016017010A2 (en) ANTI-TISSUE FACTOR MONOCLONAL ANTIBODY
MX2015017863A (en) Modulators of growth hormone receptor.
CO7240413A2 (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide